Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Adam Colborn Reviews Biosimilar Interchangeability Requirements, Advocates for Pharmacist Resources

April 28th 2024

By Cameron Santoro

Video

In an interview with Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy focuses on biosimilar interchangeability and approaches to encourage wider adoption in dispensing these medications.

The Totality of Evidence Supporting the Approval of Adalimumab Biosimilar GP2017

April 27th 2024

By Deana Ferreri, PhD

Article

A review article summarized the totality of evidence supporting the approval of the adalimumab biosimilar GP2017 (Hyrimoz; Sandoz) in the United States and Europe.

The Top 5 Biosimilar Articles for the Week of April 22

April 26th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 22, 2024.

Formycon Reports 83% Revenue Increase in 2023

April 25th 2024

By Skylar Jeremias

Article

Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7 million, according to its annual earnings report.

AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access

April 24th 2024

By Skylar Jeremias

Article

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.

AON Saves Over $243 Million With High Biosimilar Adoption

April 22nd 2024

By Skylar Jeremias

Article

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.

Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action

April 22nd 2024

By Cameron Santoro

Article

Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.

Navigating the Patent Thicket: Balancing Innovation, Biosimilar Access in the Biologics Market

April 21st 2024

By Cameron Santoro

Video

Ha Kung Wong, JD, a patent attorney, explores the challenges of "patent thickets" in the biologics market, where a complex web of patents can hinder development of more affordable biosimilar drugs. However, the discussion also highlights mechanisms to ensure fair competition and patient access.

Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch

April 20th 2024

By Deana Ferreri, PhD

Article

In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.

Selecting Between Adalimumab Biosimilars for Your Patients

April 19th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.